Search Results - "Vanoli, Fiammetta"

Refine Results
  1. 1
  2. 2
  3. 3

    Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports by Frangiamore, Rita, Giossi, Riccardo, Vanoli, Fiammetta, Tourlaki, Athanasia, Brambilla, Lucia, Maggi, Lorenzo, Mantegazza, Renato

    Published in Neurological sciences (01-05-2021)
    “…Introduction Myasthenia gravis (MG) is an autoimmune neuromuscular disease whose treatment encompasses acetylcholinesterase inhibitors, oral steroids, and…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Complement Inhibition for the Treatment of Myasthenia Gravis by Mantegazza, Renato, Vanoli, Fiammetta, Frangiamore, Rita, Cavalcante, Paola

    Published in ImmunoTargets and therapy (01-01-2020)
    “…Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80-90% of patients display…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy by Iacomino, Nicola, Vanoli, Fiammetta, Frangiamore, Rita, Ballardini, Marta, Scandiffio, Letizia, Bortone, Federica, Andreetta, Francesca, Baggi, Fulvio, Bernasconi, Pia, Antozzi, Carlo, Cavalcante, Paola, Mantegazza, Renato

    Published in Biomedicines (09-06-2022)
    “…The complement system plays a key role in myasthenia gravis (MG). Anti-complement drugs are emerging as effective therapies to treat anti-acetylcholine…”
    Get full text
    Journal Article
  9. 9

    Current drug treatment of myasthenia gravis by Vanoli, Fiammetta, Mantegazza, Renato

    Published in Current opinion in neurology (01-10-2023)
    “…Purpose of review Myasthenia Gravis (MG) is a rare neurological disorder affecting the neuromuscular junction. Clinical hallmarks are fatigability and weakness…”
    Get full text
    Journal Article
  10. 10

    Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management by Vanoli, Fiammetta, Mantegazza, Renato

    Published in Neurotherapeutics (01-04-2022)
    “…Summary Myasthenia gravis (MG) is a neurological autoimmune disorder characterized by muscle weakness and fatigue. It is a B cell–mediated disease caused by…”
    Get full text
    Journal Article
  11. 11

    Ravulizumab for the treatment of myasthenia gravis by Vanoli, Fiammetta, Mantegazza, Renato

    Published in Expert opinion on biological therapy (04-03-2023)
    “…Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on…”
    Get more information
    Journal Article
  12. 12
  13. 13
  14. 14

    miRNA in spinal muscular atrophy pathogenesis and therapy by Magri, Francesca, Vanoli, Fiammetta, Corti, Stefania

    Published in Journal of cellular and molecular medicine (01-02-2018)
    “…Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disease characterized by the selective death of lower motor neurons in the brain stem…”
    Get full text
    Journal Article
  15. 15
  16. 16

    mi RNA in spinal muscular atrophy pathogenesis and therapy by Magri, Francesca, Vanoli, Fiammetta, Corti, Stefania

    Published in Journal of cellular and molecular medicine (01-02-2018)
    “…Abstract Spinal muscular atrophy ( SMA ) is an autosomal recessive neurodegenerative disease characterized by the selective death of lower motor neurons in the…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Concordance between patient‐ and physician‐reported Myasthenia Gravis Activities of Daily Living (MG‐ADL) scores by Dewilde, Sarah, Janssen, M. F., Tollenaar, Nafthali H., Vanoli, Fiammetta, Frangiamore, Rita, Phillips, Glenn, Paci, Sandra, Mantegazza, Renato, Meisel, Andreas, Stascheit, Frauke

    Published in Muscle & nerve (01-07-2023)
    “…Introduction/Aims Myasthenia gravis (MG) is a neuromuscular disease characterized by abnormal skeletal muscle fatiguability. The MG Activities of Daily Living…”
    Get full text
    Journal Article
  19. 19

    Clinical and molecular features and therapeutic perspectives of spinal muscular atrophy with respiratory distress type 1 by Vanoli, Fiammetta, Rinchetti, Paola, Porro, Francesca, Parente, Valeria, Corti, Stefania

    Published in Journal of cellular and molecular medicine (01-09-2015)
    “…Spinal muscular atrophy with respiratory distress (SMARD1) is an autosomal recessive neuromuscular disease caused by mutations in the IGHMBP2 gene, encoding…”
    Get full text
    Journal Article
  20. 20